4
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Cognitive Symptoms of Post–COVID-19 Condition and Daily Functioning

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          How are post–COVID-19 condition self-reported cognitive symptoms associated with employment status, functional outcomes, and mood?

          Findings

          In this survey study including 14 767 individuals with post–COVID-19 condition surveyed in late 2022 to early 2023, 57% reported experiencing cognitive symptoms daily, compared with 27% with prior SARS-CoV-2 infection who did not develop post–COVID-19 condition. In those with post–COVID-19 condition, cognitive symptoms were associated with greater levels of depressive symptoms, greater reported functional impairment, and lesser likelihood of full-time employment.

          Meaning

          The findings of this study suggest that self-reported cognitive symptoms are prevalent in post–COVID-19 condition, often co-occur with depressive symptoms, and are associated with functional impairment.

          Abstract

          Importance

          The frequent occurrence of cognitive symptoms in post–COVID-19 condition has been described, but the nature of these symptoms and their demographic and functional factors are not well characterized in generalizable populations.

          Objective

          To investigate the prevalence of self-reported cognitive symptoms in post–COVID-19 condition, in comparison with individuals with prior acute SARS-CoV-2 infection who did not develop post–COVID-19 condition, and their association with other individual features, including depressive symptoms and functional status.

          Design, Setting, and Participants

          Two waves of a 50-state nonprobability population-based internet survey conducted between December 22, 2022, and May 5, 2023. Participants included survey respondents aged 18 years and older.

          Exposure

          Post–COVID-19 condition, defined as self-report of symptoms attributed to COVID-19 beyond 2 months after the initial month of illness.

          Main Outcomes and Measures

          Seven items from the Neuro-QoL cognition battery assessing the frequency of cognitive symptoms in the past week and patient Health Questionnaire-9.

          Results

          The 14 767 individuals reporting test-confirmed COVID-19 illness at least 2 months before the survey had a mean (SD) age of 44.6 (16.3) years; 568 (3.8%) were Asian, 1484 (10.0%) were Black, 1408 (9.5%) were Hispanic, and 10 811 (73.2%) were White. A total of 10 037 respondents (68.0%) were women and 4730 (32.0%) were men. Of the 1683 individuals reporting post–COVID-19 condition, 955 (56.7%) reported at least 1 cognitive symptom experienced daily, compared with 3552 of 13 084 (27.1%) of those who did not report post–COVID-19 condition. More daily cognitive symptoms were associated with a greater likelihood of reporting at least moderate interference with functioning (unadjusted odds ratio [OR], 1.31 [95% CI, 1.25-1.36]; adjusted [AOR], 1.30 [95% CI, 1.25-1.36]), lesser likelihood of full-time employment (unadjusted OR, 0.95 [95% CI, 0.91-0.99]; AOR, 0.92 [95% CI, 0.88-0.96]) and greater severity of depressive symptoms (unadjusted coefficient, 1.40 [95% CI, 1.29-1.51]; adjusted coefficient 1.27 [95% CI, 1.17-1.38). After including depressive symptoms in regression models, associations were also found between cognitive symptoms and at least moderate interference with everyday functioning (AOR, 1.27 [95% CI, 1.21-1.33]) and between cognitive symptoms and lower odds of full-time employment (AOR, 0.92 [95% CI, 0.88-0.97]).

          Conclusions and Relevance

          The findings of this survey study of US adults suggest that cognitive symptoms are common among individuals with post–COVID-19 condition and associated with greater self-reported functional impairment, lesser likelihood of full-time employment, and greater depressive symptom severity. Screening for and addressing cognitive symptoms is an important component of the public health response to post–COVID-19 condition.

          Abstract

          This survey study examines self-reported cognitive symptoms of post–COVID-19 syndrome and the association of these symptoms with individuals' employment status, functional outcomes, and mood.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          The PHQ-9: validity of a brief depression severity measure.

          While considerable attention has focused on improving the detection of depression, assessment of severity is also important in guiding treatment decisions. Therefore, we examined the validity of a brief, new measure of depression severity. The Patient Health Questionnaire (PHQ) is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders. The PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as "0" (not at all) to "3" (nearly every day). The PHQ-9 was completed by 6,000 patients in 8 primary care clinics and 7 obstetrics-gynecology clinics. Construct validity was assessed using the 20-item Short-Form General Health Survey, self-reported sick days and clinic visits, and symptom-related difficulty. Criterion validity was assessed against an independent structured mental health professional (MHP) interview in a sample of 580 patients. As PHQ-9 depression severity increased, there was a substantial decrease in functional status on all 6 SF-20 subscales. Also, symptom-related difficulty, sick days, and health care utilization increased. Using the MHP reinterview as the criterion standard, a PHQ-9 score > or =10 had a sensitivity of 88% and a specificity of 88% for major depression. PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively. Results were similar in the primary care and obstetrics-gynecology samples. In addition to making criteria-based diagnoses of depressive disorders, the PHQ-9 is also a reliable and valid measure of depression severity. These characteristics plus its brevity make the PHQ-9 a useful clinical and research tool.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            The PHQ-9

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Post-acute COVID-19 syndrome

              Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in global healthcare crises and strained health resources. As the population of patients recovering from COVID-19 grows, it is paramount to establish an understanding of the healthcare issues surrounding them. COVID-19 is now recognized as a multi-organ disease with a broad spectrum of manifestations. Similarly to post-acute viral syndromes described in survivors of other virulent coronavirus epidemics, there are increasing reports of persistent and prolonged effects after acute COVID-19. Patient advocacy groups, many members of which identify themselves as long haulers, have helped contribute to the recognition of post-acute COVID-19, a syndrome characterized by persistent symptoms and/or delayed or long-term complications beyond 4 weeks from the onset of symptoms. Here, we provide a comprehensive review of the current literature on post-acute COVID-19, its pathophysiology and its organ-specific sequelae. Finally, we discuss relevant considerations for the multidisciplinary care of COVID-19 survivors and propose a framework for the identification of those at high risk for post-acute COVID-19 and their coordinated management through dedicated COVID-19 clinics.
                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                14 February 2024
                February 2024
                14 February 2024
                : 7
                : 2
                : e2356098
                Affiliations
                [1 ]Department of Psychiatry, Weill Cornell Medicine, New York, New York
                [2 ]Machine Intelligence Group for the Betterment of Health and the Environment, Northeastern University, Boston, Massachusetts
                [3 ]Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
                [4 ]Department of Communication, School of Communication and Information, Rutgers University, New Brunswick, New Jersey
                [5 ]Department of Political Science, University of Rochester, Rochester, New York
                [6 ]John F. Kennedy School of Government and Department of Government, Harvard University, Cambridge, Massachusetts
                [7 ]Network Science Institute, Northeastern University, Boston, Massachusetts
                [8 ]Department of Political Science, Northeastern University, Boston, Massachusetts
                [9 ]Khoury College of Computer Sciences, Northeastern University, Boston, Massachusetts
                [10 ]Institute for Quantitative Social Science, Harvard University, Cambridge, Massachusetts
                [11 ]Center for Quantitative Health, Massachusetts General Hospital, Boston
                [12 ]Department of Psychiatry, Harvard Medical School, Boston, Massachusetts
                Author notes
                Article Information
                Accepted for Publication: December 20, 2023.
                Published: February 14, 2024. doi:10.1001/jamanetworkopen.2023.56098
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2024 Jaywant A et al. JAMA Network Open.
                Corresponding Author: Roy H. Perlis, MD, MSc, Massachusetts General Hospital, 185 Cambridge St, 6th Floor, Boston, MA 02114 ( rperlis@ 123456mgh.harvard.edu ).
                Author Contributions: Dr Perlis had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Gunning, Druckman, Baum, Perlis.
                Acquisition, analysis, or interpretation of data: All authors.
                Drafting of the manuscript: Jaywant, Gunning, Oberlin, Perlis.
                Critical review of the manuscript for important intellectual content: Gunning, Oberlin, Santillana, Ognyanova, Druckman, Baum, Lazer, Perlis.
                Statistical analysis: Jaywant, Santillana, Perlis.
                Obtained funding: Ognyanova, Druckman, Baum, Perlis.
                Administrative, technical, or material support: Oberlin, Druckman, Lazer.
                Supervision: Gunning, Druckman, Lazer, Perlis.
                Conflict of Interest Disclosures: Dr Gunning reported receiving grants from the National Institutes of Health (NIH), Akilit, and a principal investigator–initiated grant to support randomized clinical trials on cognitive symptoms of post–COVID-19 condition outside the submitted work. Dr Baum reported receiving grants from the National Science Foundation and the NIH outside the submitted work. Dr Perlis reported receiving personal fees from the Burrage Capital Investment Fund, Genomind Genomics, Circular Genomics, and Takeda Preclinical scientific advising outside the submitted work; and Dr Perlis is an associate editor for JAMA Network. No other disclosures were reported.
                Funding/Support: The survey was supported in part by the National Science Foundation (Drs Ognyanova, Druckman, Baum, and Lazer) and the National Institute of Health (Drs Lazer and Perlis).
                Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Disclaimer: Dr Gunning and Dr Perlis are Associate Editors of JAMA Network Open but were not involved in any of the decisions regarding review of the manuscript or its acceptance.
                Data Sharing Statement: See Supplement 2.
                Article
                zoi231649
                10.1001/jamanetworkopen.2023.56098
                10867690
                38353947
                5c6d82f6-1b1b-43b0-a6df-a81528aed0a6
                Copyright 2024 Jaywant A et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 31 October 2023
                : 20 December 2023
                Categories
                Research
                Original Investigation
                Online Only
                Infectious Diseases

                Comments

                Comment on this article